Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNIC, INC.IMUX · Entity 6306 | Director | June 15, 2022 | June 18, 2022 |
| Omega Alpha SPACOMEG · Entity 143846 | Chief Scientific Officer | January 06, 2021 | January 06, 2021 |
| SOPHiA GENETICS SASOPH · Entity 5228 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNIC, INC.
Report date June 15, 2022 · Filed June 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2032-06-15 | Direct | 10,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in monthly increments over a period of one year from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in monthly increments over a period of one year from the grant date.
Omega Alpha SPAC
Report date January 06, 2021 · Filed January 06, 2021
This filing explicitly reported no securities owned.
SOPHiA GENETICS SA
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 522,860 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 19,724 · Balance 522,860 F1: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2036-06-18 | Direct | 138,569 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 28,818 · Balance 138,569 F2: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.
F2: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantShare Option (Right to Buy) · Derivative | 28,818 | $5.46 Strike: $5.46 | $157,346.28 |
DisclosureSEC source: 0001840706-26-000222 · wk-form4_1782158492.xml · derivative · entry 2 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,569 Underlying: Ordinary Shares · 28,818 shares Expires 2036-06-18 F2 · derivative.exercise_date: The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:01 UTC | SOPHiA GENETICS SA SOPH · Entity 5228 | GrantOrdinary Shares | 19,724 | $5.46 | $107,693.04 |
DisclosureSEC source: 0001840706-26-000222 · wk-form4_1782158492.xml · nonDerivative · entry 1 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,860 F1 · shares: Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders. Read SEC document |
| June 15, 2022 Filed Jun 18, 2022 01:33 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001193805-22-000971 · e621758_4-ossipow.xml · derivative · entry 1 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:02 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001193805-21-000868 · e620713_4-ossipow.xml · derivative · entry 1 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 21:47 UTC | IMMUNIC, INC. IMUX · Entity 6306 | GrantStock Option · Derivative | 29,959 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001193805-19-000671 · e618567_4-ossipow.xml · derivative · entry 1 Ossipow Vincent · CIK 0001773679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,959 Underlying: Common Stock · 29,959 shares Expires 2029-07-22 F1 · derivative.exercise_date: 9,986 of the options vest in monthly increments over a period of one year from the grant date, and 19,973 of the options vest in monthly increments over a period of three years from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.